Tandem Diabetes Q1 sales up 22% to $234.4 million; GAAP net loss $130.6 million
Tandem Diabetes reported first quarter 2025 worldwide sales of $234.4 million, up 22% from $191.7 million a year earlier, and reaffirmed its 2025 GAAP sales guidance of $997 million to $1.007 billion. GAAP net loss widened to $130.6 million, or $1.97 per share, from $42.7 million, or $0.65 per share, mainly due to $75.2 million of acquired in-process research and development expenses, so sales growth and the larger loss point in different directions for shareholders.
Key points
- Worldwide sales rose to $234.4 million from $191.7 million; U.S. pump sales rose 19% on a GAAP basis.
- GAAP net loss was $130.6 million, compared with $42.7 million; non-GAAP net loss was $44.2 million, compared with $41.6 million.
- Adjusted EBITDA was negative $4.7 million, compared with negative $14.4 million a year earlier.
- Full-year 2025 GAAP sales guidance of $997 million to $1.007 billion was reaffirmed.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.